The company’s research, scheduled for a poster presentation on November 9, 2026, details how ATG-207 leverages a peptide-masked and TGFβRIII-biased domain paired with an anti-CD3 antibody. By utilizing this structure, the therapy seeks to suppress pathogenic T cells while simultaneously promoting the differentiation of regulatory T cells, a mechanism designed to bypass the safety limitations often associated with systemic TGF-β delivery.

In laboratory and animal models, the candidate demonstrated significant therapeutic potential. According to the company, ATG-207 showed efficacy in treating experimental autoimmune encephalomyelitis and collagen-induced arthritis, while maintaining favorable stability and safety profiles in toxicology studies. These findings suggest that receptor-biased, context-restricted delivery may offer a more precise approach to restoring durable immune tolerance than conventional therapies.